Boston Sci picks up in-development endoscopic tissue retractor from LumenR

Boston Scientific

Boston Scientific is bolstering its endoscopy pipeline with the acquisition of an in-development tissue retractor from Newark, CA’s LumenR. The system is intended for the endoscopic removal of lesions in the gastrointestinal tract.

The LumenR Tissue Retractor System is designed to enhance endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) procedures by providing improved visualization of lesions and a stable working environment, according to a statement. These procedures are less invasive alternatives to surgical resection to remove precancerous lesions and malignant tumors in the esophagus, stomach or colon.

Endoscopic treatment for colorectal, esophageal and gastric cancers often includes ESD and EMR procedures. Having a tool to facilitate these procedures could be a boon for the more than 137,000 people in the U.S. who will be diagnosed with colorectal cancer this year.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"We are excited about the potential of the LumenR system to improve visibility and control during ESD and EMR procedures and improve quality of life for patients," said Art Butcher, Boston Scientific senior vice president and president of its endoscopy business, in the statement. "Every year, patients around the world undergo open gastrointestinal surgery that has a profound impact on their lives. By bringing this innovative technology forward, we have an opportunity for more physicians to treat patients successfully through less invasive endoscopic procedures."

Boston Sci will fold the LumenR system into its endoscopy pipeline, developing and evaluating the system ahead of commercialization, according to the statement. Terms of the deal were not disclosed.

In September, Boston Scientific agreed to acquire gastrointestinal specialist EndoChoice to the tune of $210 million. Endoscopic imaging tools, diagnostics and infection-control products are among the products Boston Sci expects to integrate into its endoscopy unit. These include EndoChoice’s Fuse Endoscopy System, which affords a 330-degree field of view, allowing clinicians to see nearly twice as much as a traditional endoscope would.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.